Iowa Oral Performance Instrument for Tongue Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to learn more about tongue strength and endurance in people with tongue cancer. Researchers will use the Iowa Oral Performance Instrument (IOPI) Tongue Strength Trainer to measure tongue strength. Participants will be divided into two groups: one will receive standard care plus use the IOPI, while the other will receive standard care only. Individuals scheduled for their first surgery for oral tongue cancer, without previous treatments in the head or neck area, might be suitable candidates. As an unphased trial, this study offers participants the chance to contribute to valuable research that could enhance future treatment options.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that the Iowa Oral Performance Instrument is safe for measuring tongue strength?
Research shows that the Iowa Oral Performance Instrument (IOPI) is a safe and reliable tool for measuring tongue strength. Studies have demonstrated that the IOPI measures tongue pressure without causing harm. For example, a review found that the IOPI provides consistent results when assessing tongue strength and endurance. Additionally, research with patients who have head and neck cancer showed improvements in tongue strength without major side effects.
Overall, the IOPI is well-tolerated, and these studies have not linked it to any serious negative effects. This suggests that using the IOPI for tongue strength training is safe for participants.12345Why are researchers excited about this trial?
Researchers are excited about the Iowa Oral Performance Instrument (IOPI) for tongue cancer because it offers a novel approach to rehabilitation. Unlike standard care, which may focus on surgical or medication-based interventions, the IOPI targets muscle strength directly by training the tongue muscles. This method could enhance recovery of tongue function post-surgery, potentially improving speech and swallowing abilities more effectively than current options. By stratifying treatment based on the type of glossectomy, this approach also allows for personalized therapy, which could lead to better outcomes for patients.
What evidence suggests that the Iowa Oral Performance Instrument is effective for tongue cancer?
Research has shown that the Iowa Oral Performance Instrument (IOPI) can strengthen the tongue and increase its endurance. In this trial, participants in the treatment group will receive standard care plus intervention with the IOPI. Studies have found that individuals achieved higher maximum tongue pressure (MIP) after training with the IOPI, indicating increased tongue strength. Another study demonstrated that those who used the IOPI as part of an oral rehabilitation program improved their mouth movement. These findings suggest that the IOPI can be a useful tool for enhancing tongue function, particularly for individuals who have undergone surgery for tongue cancer.12356
Who Is on the Research Team?
Louise Cunningham
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for individuals with oral tongue cancer. Specific eligibility criteria are not provided, so it's important to contact the study organizers for detailed requirements on who can participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive standard of care plus intervention with the Iowa Oral Performance Instrument (IOPI) or standard of care alone
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Iowa Oral Performance Instrument (IOPI) Tongue Strength Trainer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor